WP
ITCI

WealthPLAN Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

WealthPLAN Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$2.74K Sell
187
-187
-50% -$7.56K ﹤0.01% 817
2016
Q2 		$7.27K Buy
+374
New +$13.4K ﹤0.01% 1860

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

WealthPLAN Partners's ITCI Position: Q3 2016 in Review

WealthPLAN Partners reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 50% in Q3 2016, selling an estimated $7.56K and leaving 187 shares worth $2.74K. The position accounts for ﹤0.01% of the portfolio, ranked #817.

WealthPLAN Partners first reported a position in ITCI in Q2 2016 and has held it in 2 quarters since. The position peaked at $7.27K in Q2 2016. 132 funds tracked by Wall St. Rank hold ITCI as of Q3 2016.

  • WealthPLAN Partners held 187 shares of Intra-Cellular Therapies Inc. worth $2.74K as of Q3 2016.
  • WealthPLAN Partners sold 187 Intra-Cellular Therapies Inc. shares in Q3 2016, an estimated $7.56K.
  • Intra-Cellular Therapies Inc. made up ﹤0.01% of WealthPLAN Partners's portfolio in Q3 2016, its #817 holding.
  • WealthPLAN Partners first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and has held it in 2 quarters since.
  • WealthPLAN Partners's Intra-Cellular Therapies Inc. position peaked at $7.27K in Q2 2016.
  • 132 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2016.

Based on WealthPLAN Partners's 13F filing for Q3 2016, filed 9 Dec 2016.